Daily Stock List
Sunvalley Solar, Inc. (SSOL)
PennyStocks24 and Xtremepicks reported on Sunvalley Solar, Inc. (SSOL), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Sunvalley Solar, Inc. is a solar power technology and system integration enterprise. It provides complete solar energy technology, system design, installation, equipments, and technical support for electrical contractors, builders, homeowners, government entities, and businesses/commercial buildings. The Company provides an all-in-one service for customers' solar system needs. This is from system design and permitting, to installation and final inspection.
Sunvalley Solar has its headquarters in Walnut, California. The Company was previously known as West Coast Solar Technologies Corp. Sunvalley Solar’s shares trade on the OTC Markets Group’s OTCQB.
The Company’s Research and Development (R&D) team consists of PhDs in Optoelectronics. The team specializes in photovoltaic panel technologies (coating and focusing). Sunvalley Solar’s R&D team’s projects include 975 kW commercial solar power systems for distribution warehouses and manufacturing companies, and 1 MW commercial solar power systems for agriculture farms and cold storage facilities.
Sunvalley Solar’s growth strategy includes developing and commercializing its proprietary solar technologies. This includes its coating and focusing technologies, racking, and panel cleaning system.
Sunvalley Solar’s growth strategy also includes promoting and enhancing its brand and reputation in solar design and integration and expanding its installation business, and developing a PV panel manufacturing capability to provide high efficiency and low cost solar panels to the U.S. market. Additionally, the Company’s focus is getting involved in the private power providing business (Distributed Power Plants).
The Company is a leading solar electric equipment wholesale distributor for solar photovoltaic equipment of manufacturers. Sunvalley Solar specializes in packaged solar system solutions. Its emphasis is Solar System Design and Installation, Solar Equipment Distribution, Solar Technology Research and Development, and as a National Solar Technical Support and Service Center.
In 2014, Sunvalley Solar was awarded a new 676.5 KW solar system installation contract for Raven Farms in Selma, California. When completed, the system will generate greater than 1.1 million kWh of clean energy to offset 75 percent of the facility's electric bill. The expectation is that the system will pay for itself in approximately four years and lessen the plant's carbon footprint by more than1.6 million pounds of CO2 each year.
Sunvalley Solar, Inc. (SSOL), closed Wednesday's trading session at $0.0172, up 21.13%, on 770,962 volume with 31 trades. The average volume for the last 60 days is 148,944 and the stock's 52-week low/high is $0.009/$0.034.
TelUpay International, Inc. (TLPY)
Market Authority, Pumps and Dumps, Value Penny Stocks, TryBestPennyStocks.biz, FatCat Stocks, DSR News, HotStockProfits, Whisper from Wall Street, and Otcstockexchnage reported on TelUpay International, Inc. (TLPY), and today we highlight the Company, here at the QualityStocks Daily Newsletter.
TelUpay International, Inc. is the parent company of the TelUPay Group, which has developed the next generation of secure mobile banking/payments technology (MBPS). The design of it is for banks, mobile operators (MNOs), money transfer operators (MTOs), payment processors, retailers/merchants, credit card companies, microfinance, large corporations and other financial institutions. Incorporated in the State of Nevada, TelUPay International has operations and partnerships in the Philippines, Indonesia, Peru, Bangladesh, the United Kingdom, Guam and Micronesia.
TelUPay provides customized services and continuously develops new applications. The Company’s mWallet is a stand-alone, server-side, mobile account technology. It is specifically designed for Mobile Operators, Money Transfer Operators and other large network operators. TelUPay’s mPOS mobile payment solutions equip merchants to accept mobile payments.
The Company’s Mobile ATM (ATM Lite) enables consumers to have all the facilities of an ATM service. Registration with the user's bank enables the consumer to pre-authorize an amount of money to be available to spend. Regarding its ATM API, TelUPay's portfolio of its 4th Generation technology is an ATM enabling technology. It leverages banks existing global investments in ATM networks to complement them.
TelUPay's bank-grade MBPS uses the most secure encryption technology available for the bank and the end-user. Services include fund transfers, P2P remittances domestically and internationally, bill payments, merchant payments, mobile airtime purchases, balance inquiries, and a variety of other services designed to provide the ultimate convenience to the consumer at the lowest possible cost.
Yesterday, TelUPay announced that it signed a Memorandum of Understanding (MOU) with Xytrix Systems Corp. to manufacture self-service payment kiosks. Xytrix provides the hardware and TelUPay provides its payment technologies and its aggregator services to allow Filipino consumers to purchase mobile airtime, pay bills, top-up stored value cards for transit systems, convenience stores and restaurants, purchase prepaid electricity and conduct remittances via national remittance operators.
TelUpay Management's objective is to deploy 1,000 kiosks by Q2 2016 in strategic locations such as convenience stores, call centers, BPO's and the Philippines EPZAs factories, servicing millions of Filipino workers.
TelUpay International, Inc. (TLPY), closed Wednesday's trading session at $0.1645, up 18.82%, on 5,834,033 volume with 765 trades. The average volume for the last 60 days is 1,209,923 and the stock's 52-week low/high is $0.055/$0.50.
AntriaBio, Inc. (ANTB)
Ceocast News and PennyStocks24 reported on AntriaBio, Inc. (ANTB), and we are highlighting the Company as well, here at the QualityStocks Daily Newsletter.
Founded in 2010, AntriaBio, Inc. is a biopharmaceutical company focusing on developing novel extended release therapies. The Menlo Park, California based Company develops novel extended release therapies through combining proprietary formulation and manufacturing capabilities with well-known molecules to significantly improve standards of care. It develops innovative approaches to fulfill unmet clinical needs through applying its formulation capabilities to improve existing therapies. AntriaBio’s shares trade on the OTC Markets’ OTCQB.
AntriaBio’s lead product candidate is AB101. This is an injectable once-weekly basal insulin for type 1 and type 2 diabetes. AB101 addresses a $10 billion market where the current standard of care is a once-daily basal insulin injection. AB101 is formulated from human recombinant insulin. This is different from existing basal insulin replacement therapies, which use synthetic insulin analogues.
AB101 is now in preclinical development. It is to be administered by subcutaneous injection. AB101 is intended for use in patients with Type 1 and Type 2 diabetes who require basal insulin for the control of hyperglycemia. The design of the formulation is to release human insulin slowly and uniformly over a period of approximately one week without an adverse initial burst of insulin.
AntriaBio announced recently that it successfully completed a series of in vitro and multi-species animal pharmacology studies for AB101. The studies assessed the receptor pharmacology, pharmacokinetics, and pharmacodynamics of AB101 and support potential proof-of-concept for a once-weekly basal insulin in patients.
The Company is presently engaged in additional studies. This includes continuing toxicology studies that would support the filing of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for AB101 and the ensuing launch of a clinical study in type 1 diabetes patients in 2015.
AntriaBio also recently announced that Dr. Hoyoung Huh will expand his role to Chair the Company's business development efforts, product pipeline strategy, and Scientific Advisory Board. Dr. Huh is one of AntriaBio’s co-founders and member of the Board of Directors.
AntriaBio, Inc. (ANTB), closed Wednesday's trading session at $1.75, down 2.23%, on 1,455 volume with 5 trades. The average volume for the last 60 days is 5,062 and the stock's 52-week low/high is $0.90/$4.00.
BIO-key International, Inc. (BKYI)
SmallCap Voice, PennyStocks24, Planet Penny Stocks, Buzz Stocks, PennyStockProphet, StockOnion, SecretStockPromo, and Penny Pick Finders reported earlier on BIO-key International, Inc. (BKYI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.
BIO-key International, Inc. is a leader in fingerprint biometric identification technologies, secure cloud- and device-based mobile credentialing and identity verification solutions. The Company develops and delivers advanced identification solutions to commercial and government enterprises, integrators, and custom application developers. BIO-key International lists on the OTC Markets’ Group’s OTCQB. The Company is headquartered in Wall, New Jersey.
BIO-key's technology is offered directly or by market leading partners globally. BIO-key’s solutions are used in local embedded original equipment manufacturer (OEM) products and some of the world's largest identification deployments to improve security, guarantee identity, and help reduce identity theft.
The Company helps customers reduce risk and protect the value of their services and assets, while minimizing the continuing costs for Access Control and Identity Management. BIO-key’s biometric finger identification technology is award winning, high performance, scalable, cost-effective, and easy-to-deploy. It accurately identifies and authenticates users of wireless and enterprise applications.
The Company’s products include SideSwipe® Mini Fingerprint Reader, Web-key®, VST-Vector Segment Technology™, ID Director for Allscripts HER, ID Director for EpicCare, ID Director for CA SiteMinder, ID Director for IBM ISAM for Web, BIO-key BSP for IBM ESSO, BIO-key BSP for Oracle Access Manager, and ID Director for Windows.
In January, BIO-key International announced that it received initial purchase orders from hospitals in New York, Ohio, Kentucky, and California, with a combined value of $130,000. These initial contracts will represent more than $400,000 in revenue in 2015. The Company will provide fingerprint authentication solutions to these hospitals and others, to raise the level of security and convenience for healthcare providers as they update patient records and process Electronic Prescription of Controlled Substances (EPCS).
BIO-key International’s fingerprint authentication solutions support its Meaningful Use roadmaps and meet compliance guidelines from the U.S. Drug Enforcement Agency (DEA) and respective State Boards of Pharmacy. Fingerprint authentication has become the preferred authentication option in Healthcare for meeting Meaningful Use, EPCS, I-STOP, CPOE and other requirements.
BIO-key International, Inc. (BKYI), closed Wednesday's trading session at $0.21, even for the day, on 101,932 volume with 23 trades. The average volume for the last 60 days is 2,598 and the stock's 52-week low/high is $0.14/$0.594.
Emisphere Technologies, Inc. (EMIS)
PennyStockRumors.net, AddictivePennyStocks, and PennyStocks24 reported earlier on Emisphere Technologies, Inc. (EMIS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.
Emisphere Technologies, Inc. is a specialty pharmaceutical company listed on the OTCQB. It has been transformed recently from a delivery systems development company into a broader commercial-stage entity. The Company is focusing on its first commercial product, oral Eligen® B12. It is preparing to launch commercial operations. Emisphere Technologies is based in Roseland, New Jersey.
The Company’s pipeline includes product candidates that have reached clinical development and a variety of preclinical research and development programs. Emisphere is carrying out these programs in collaboration with pharmaceutical and biotechnology companies, and also independently.
Emisphere is preparing to launch its first prescription product, oral Eligen®B12, in the U.S. Further to Eligen®B12, the Company employs its proprietary Eligen® Technology to create new oral formulations of therapeutic agents.
Its Oral Eligen® B12 meets significant unmet patient and medical needs through combining B12 with Emisphere’s proprietary delivery system technology. Through building on the oral Eligen® B12 product, Emisphere’s intention is to establish a sound product portfolio platform on which to expand its B12 therapeutic franchise and expand internal new product development with new therapeutic agents.
In addition, the Company will continue to develop its existing drug delivery carrier partnerships and expand its carrier business through looking for and engaging in new global licensing opportunities. Its strategy is to reemphasize the commercialization of Eligen® Oral B12, build new high-value partnerships, evaluate new commercial opportunities, and promote new uses for the Eligen® Technology.
The Company has developed an oral formulation of Eligen® B12 (1000 mcg) for use by B12 deficient individuals. It is covered by patent protection in the United States through approximately 2029. Moreover, Novo Nordisk is using Emisphere's Eligen® Technology to develop oral formulations of Novo Nordisk's insulin and GLP-1 receptor agonists.
Emisphere Technologies continues to emphasize the commercialization of oral Eligen®) B12, seek new high-value partnerships, evaluate new prescription Medical Foods commercial opportunities, reprioritize the product pipeline, and promote new uses for the Eligen® Technology. All key oral Eligen® B12 launch initiatives are in progress.
Last month, Emisphere Technologies highlighted positive Phase 2 data from Eligen® licensee Novo Nordisk regarding OG217SC, the oral formulation of semaglutide, a long-acting human GLP-1 analogue, which stimulates insulin and suppresses glucagon secretion in a glucose-dependent manner. OG217SC is provided in a tablet formulation with an absorption-enhancing excipient, SNAC. SNAC is included in the Eligen® Carrier Concept.
Novo Nordisk announced last month that it successfully completed the Phase 2 trial for OG217SC, investigating dose range, escalation, efficacy and safety of once-daily oral semaglutide compared with oral placebo or once-weekly subcutaneously administered semaglutide in approximately 600 people with type 2 diabetes treated for 26 weeks.
Emisphere Technologies, Inc. (EMIS), closed Wednesday's trading session at $0.8275, up 3.44%, on 264,758 volume with 113 trades. The average volume for the last 60 days is 17,385 and the stock's 52-week low/high is $0.20/$0.848.
PharmaCyte Biotech, Inc. (PMCB)
Penny Stock Beats, PennyDoctor, Wallstreet Profiler, MicroCap, OTCMagic, FatCat Stocks, Wall Street Beauties, WINNINGOTC, and SMS Penny Picks reported this month on PharmaCyte Biotech, Inc. (PMCB), and today we also report on the Company, here at the QualityStocks Daily Newsletter.
OTCQB-listed PharmaCyte Biotech, Inc. is a clinical stage biotechnology company. It centers on developing targeted treatments for cancer and diabetes using its signature live cell encapsulation technology, Cell-in-a-Box®. This unique and patented technology is being used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. In addition, it is working towards improving the quality of life of patients with advanced pancreatic cancer and on developing treatments for other kinds of solid cancerous tumors. PharmaCyte Biotech has its corporate headquarters in Silver Spring, Maryland.
PharmaCyte’s treatment for pancreatic cancer involves low doses of the recognized anticancer prodrug ifosfamide, together with encapsulated live cells, which convert ifosfamide into its active or "cancer-killing" form. These capsules are placed as close to the cancerous tumor as possible. This is to enable the delivery of the highest levels of the cancer-killing drug at the source of the cancer.
Furthermore, PharmaCyte Biotech is developing treatments for cancer founded upon chemical constituents of the Cannabis plant, known as cannabinoids. The Company is examining ways to exploit the benefits of Cell-in-a-Box® technology in optimizing the anticancer effectiveness of cannabinoids, while minimizing or outright eliminating the debilitating side effects usually associated with cancer treatments.
The live-cell encapsulation technology employed by PharmaCyte Biotech is a way to enclose living cells in protective “cocoons” around the size of the head of a pin. The Company encapsulates living cells, not drugs. Each capsule can enclose approximately 10,000 cells. This number can vary depending upon the size of the cells encapsulated.
Recently, PharmaCyte Biotech announced that Dr. Matthius Lohr, Chairman of its Scientific Advisory Board, together with his colleagues Dr. Verbeke, Dr. Severin Karlsson and Dr. Del Charro from the Karolinska Institute in Stockholm, Sweden, published a medical and scientific review article, which is directed to improving the treatment of pancreatic cancer. The article titled "Pathology reporting of pancreatic cancer following neoadjuvant chemotherapy: Challenges and uncertainties" appeared in the distinguished cancer journal Cancer Treatment Reviews.
PharmaCyte Biotech, Inc. (PMCB), closed Wednesday's trading session at $0.10325, up 0.93%, on 2,010,288 volume with 181 trades. The average volume for the last 60 days is 1,663,349 and the stock's 52-week low/high is $0.095/$0.493.
Advanced Credit Technologies, Inc. (ACRT)
That Girl Stocks and PennyStocks24 reported previously on Advanced Credit Technologies, Inc. (ACRT), and today we choose to highlight the Company, here at the QualityStocks Daily Newsletter.
Advanced Credit Technologies, Inc. has launched a new software platform, which enables the average American to raise their personal credit scores from the privacy of their home or office via the Internet. The Company has developed TURNSCOR, which is a user friendly software, combined with a few basic steps, to educate the general public on how to simply remove negative, outdated, inaccurate, or incorrect items from their credit profiles. Advanced Credit Technologies lists on the OTCQB. The Company is headquartered in Apple Valley, Minnesota.
Advanced Credit Technologies’ clients are given access to a complete back office dashboard, a detailed video training library, a personalized e-book, and all of the technical support needed to use the simple platform. The Company’s TURNSCOR PRO has been developed as an ancillary product for the wholesale verticals, to offer a value added product to its clients free of charge to build lasting relationships.
It developed TURNSCOR PRO to help large and small businesses nationwide build lasting relationships with clients who may have a blemish or error on their credit profiles. TURNSCOR PRO provides a wide-ranging solution to all of a small business’ limited financial resources, in order to gain market share. TURNSCOR PRO personalizes a business with a white labeled back office dashboard. It also provides an integrated training library, has mass e-mail capability, and sends a business instant notifications when its clients have made a positive change to their credit scores.
Recently, Advanced Credit Technologies and Capstone Data signed a processing agreement. The agreement will allow both companies to maximize opportunities in the global prepaid and emerging payments sector. Advanced Credit Technologies’ uniquely positioned patent pending technology and credit repair platform, supported by Capstone Data's industry leading global processing and technology platform, will enable both companies to leverage the global payments market, estimated at $1.23 trillion by 2020. Capstone Data is a California-based payments processing and technology enterprise.
Today, Advanced Credit Technologies announced that it entered into a joint marketing effort with Capstone Data to launch its TurnScor PrePaid Master Card. The unique features of the TurnScor Card include free access to the TURNSCOR Credit Repair software ($399.00 Retail Value); Sequre Lock: complete freedom from fraud and hackers, smart phone "Real Time Prevention". (Compatible with iPhone, Android, and most smart phones), as well as Shopping Network, with savings of $4500 annually from more than 300,000 merchants.
Advanced Credit Technologies, Inc. (ACRT), closed Wednesday's trading session at $0.084, up 11.85%, on 259,100 volume with 24 trades. The average volume for the last 60 days is 77,371 and the stock's 52-week low/high is $0.015/$0.10.
VistaGen Therapeutics, Inc. (VSTA)
The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $12.00, up 50.00%, on 259 volume with 2 trades. The stock’s average daily volume over the past 60 days is 626, and its 52-week low/high is $3.16/$15.00.
VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs
VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.
By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve. According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.
Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months. VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits. In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations.
AV-101, VistaGen's lead small molecule prodrug candidate, has successfully completed Phase I clinical development in the U.S. for treatment of neuropathic pain, a serious and chronic condition affecting millions of people worldwide, depression, and other neurological diseases and conditions. To date, the U.S. National Institutes of Health (NIH) has awarded VistaGen over $8.75 million for development of AV-101. Management anticipates strategically out-licensing AV-101 to a development and marketing partner in 2013.
VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer
VistaGen Therapeutics, Inc. Company Blog
VistaGen Therapeutics, Inc. News:
VistaGen and NIH Sign Agreement for NIH-Sponsored Phase 2 Study of Orally-Active AV-101 in Major Depressive Disorder
Dr. Gerard Sanacora Joins VistaGen's Clinical and Scientific Advisory Board
VistaGen Signs Letter of Intent With National Institute of Mental Health for NIH-Sponsored Phase 2 Clinical Study of AV-101 in Major Depressive Disorder
Zenosense, Inc. (ZENO)
The QualityStocks Daily Newsletter would like to spotlight Zenosense, Inc. (ZENO). Today, Zenosense, Inc. closed trading at $0.131, up 0.69%, on 37,480 volume with 19 trades. The stock’s average daily volume over the past 60 days is 34,391, and its 52-week low/high is $0.1301/$1.00.
Zenosense, Inc. (ZENO) is developing and intends to market a novel device to enable hospitals to detect Methicillin-resistant Staphylococcus Aureus (MRSA) bacterial contamination, a major constituent of Hospital Acquired Infections (HAIs). The annual costs of treating hospitalized MRSA patients are estimated to be between $3.2 billion and $4.2 billion in the United States alone. MRSA infected patients are likely to spend three times as long in a hospital stay at three times the cost, and are five times more likely to die than an uninfected patient.
Early detection of MRSA and HAIs in general is vital. Recent studies suggest that implementing prevention practices can lead to up to a 70 percent reduction in certain HAIs with a financial benefit of using these prevention practices estimated to be as high as $25.0 billion to $31.5 billion in medical cost savings in the United States alone (according to a report by the Centers for Disease Control and Prevention, part of the US Department of Health and Human Sciences). Currently, no cost effective early detection device is available.
The Zenosense MRSA detection device is expected to act like a “smoke detector” for MRSA; designed to detect MRSA in the environment or infected patient, even before a patient demonstrates any obvious symptoms, satisfying this huge unmet need.
Zenosense has an agreement with leading European sensor developer Sgenia Group, which is developing such a device exclusively for Zenosense through their subsidiary Zenon Biosystem. The estimated manufacturing cost per device is under $100 USD and possibly as low as $50 USD. The Zenosense device, utilizing established Sgenia programming and patent-pending hardware, utilizes a single sensor to perform an infinite number of scans, creating tens of thousands of "virtual sensors". The low cost and compact design of the Zenosense device, if successfully developed, would make it possible to be worn by individuals, as well as placed in numerous sensitive areas in the healthcare setting.
Zenosense has a streamlined management team experienced in high-level marketing in the medical sector, supported by the outsourced Zenon Biosystem scientific/development team of qualified personnel with extensive knowledge and experience in the development of sensors. Both of these teams will fuse together through a high level advisory board of experienced professionals. A cost-effective Zenosense MRSA detection device, once developed, is expected to be in high demand, driven by patient safety, cost and insurance considerations. Disclaimer
Zenosense, Inc. Company Blog
Zenosense, Inc. News:
Zenosense, Inc. - Hospital Collaboration - 400 Person Lung Cancer Detection Trial
Zenosense, Inc.; Stock Now DTC DWAC/FAST Eligible
Zenosense, Inc. Reports Manufacturing of Pre-Commercial Lung Cancer Detection Device
Save The World Air, Inc. (ZERO)
The QualityStocks Daily Newsletter would like to spotlight Save The World Air, Inc. (ZERO). Today, Save The World Air, Inc. closed trading at $0.4596, off by 0.09%, on 85,214 volume with 14 trades. The stock’s average daily volume over the past 60 days is 125,674, and its 52-week low/high is $0.3401/$0.95.
Save The World Air, Inc. (ZERO) (“STWA”) provides the global energy industry with patent-protected industrial equipment designed to deliver measurable performance improvements to crude oil pipelines. Developed in partnership with leading crude oil production and transportation entities, STWA’s high-value solutions address the enormous capacity inadequacies of domestic and overseas pipeline infrastructures that were designed and constructed prior to the current worldwide surge in oil production.
In support of our clients’ commitment to the responsible sourcing of energy and environmental stewardship, STWA combines scientific research with inventive problem solving to provide energy efficiency ‘clean tech’ solutions to bring new efficiencies and lower operational costs to the upstream, midstream and gathering sectors. STWA’s flagship product, AOT (Applied Oil Technology) improves the economics of transporting crude oil by reducing the viscosity of oil in pipelines. Once deployed on pipeline pumping stations, production and transportation companies benefit from the safer, more cost-effective delivery of greater volumes of oil while reducing energy consumption at pumping stations and lowering CO2 emissions.
The AOT technology is the result of years of research conducted at Temple University (Philadelphia, Penn.) and is the world’s first ASME-certified industrial hardware to use the principles of electrorheology, the study of applying non-uniform electrical fields to change the mechanical behavior of fluids, to significantly reduce the viscosity of crude oil within pipelines during maximum flow conditions. Field tested by the U.S. Department of Energy, independent testing laboratories such as ATS RheoSystems and fabricated to exacting industry standards by STWA’s supply chain partners, the efficacy of AOT to increase flow rates, prevent bottlenecks, reduce pump station power consumption, enhance pipeline integrity and optimize flow assurance has been proven repeatedly in the lab and on a 300,000 barrel per day pipeline.
STWA is also commercializing STWA Joule Heat, an energy-efficient technology for heating crude oil in pipelines to improve flow. Unlike traditional trace heating systems which generate heat via a resistive trace heating element which transfers energy into the oil, the STWA solution applies an electrical field directly to oil, generating heat within the flow itself. The result is optimal heat conductivity and performance with less power and in a smaller form factor.
Guided by a dynamic management team led by Greggory Bigger, Chief Executive Officer, Chairman and a strong independent board of directors of energy industry veterans, STWA is a revenue generating company with a solid cash position, clean balance sheet and a proven ability to develop and deliver industrial-grade equipment that support the company’s mission and enhance shareholder value. As the exclusive licensee of oil viscosity reduction processes developed at Temple University and owner of 48 worldwide patents related to the use of electricity to change the mechanical behavior of oil and liquid natural gas, STWA is well-positioned to capitalize on the explosive growth opportunities in the global crude oil production and transportation sector. More information is available at: www.stwa.com. Disclaimer
Save The World Air, Inc. Company Blog
Save The World Air, Inc. News:
STWA Sets Date for Its Year-End 2014 Earnings Results Release and Conference Call
STWA Deploys AOT(TM) Viscosity Reduction System on Condensate Pipeline in Eagle Ford
STWA (ZERO) Key Management Featured in Exclusive QualityStocks Interview
Well Power Inc. (WPWR)
The QualityStocks Daily Newsletter would like to spotlight Well Power Inc. (WPWR). Today, Well Power Inc. closed trading at $0.0224, off by 0.44%, on 234,564 volume with 19 trades. The stock’s average daily volume over the past 60 days is 109,985, and its 52-week low/high is $0.019/$0.83.
Well Power Inc. (WPWR) has secured the licensing rights to Texas with the first right of refusal on the other US states to a new technology solution to process waste natural gas, such as vented, flared or stranded gas, into “clean power” and engineered fuels, including no-sulphur diesel and diluents. Based on proprietary technology, this solution is mobile, high-yield and can be deployed with minimum capital expenditure.
The company plans to be able to provide its technology with full-service engineering, design, construction, modular fabrication, maintenance and construction management services to clients in the upstream areas of exploration and production. Well Power will also offer consulting services, process assessments, facility appraisals, feasibility studies, technology evaluations, project finance structuring and support, and multi-client subscription services.
Approximately 2.4 million barrels of oil equivalent is wasted each day by gas flaring alone, resulting in $10 billion of lost revenue and 400 million metric tons of CO2 equivalent global greenhouse gas emissions each year. Additionally, environmental degradation associated with gas flaring has been shown to have a significant impact on local populations, often resulting in loss of livelihood and severe health issues.
Well Power’s Micro Refinery Unit (MRU) offers the opportunity to create value from a wasted resource while simultaneously enabling wider access to energy, improved environmental conditions, and economic development for local populations. By eliminating legacy flaring and minimizing new flaring, the company is well positioned to take a leadership role in the ongoing push for sustainable resource development and energy efficiency. Disclaimer
Well Power Inc. Company Blog
Well Power Inc. News:
Well Power - Letter from President to Shareholders
Well Power Inc. to host second webinar on proprietory micro-refinery technology
Well Power Inc. Information to be Available through S&P Capital IQ Corporation Records Program
Resort Savers, Inc. (RSSV)
The QualityStocks Daily Newsletter would like to spotlight Resort Savers, Inc. (RSSV). Today, Resort Savers, Inc. closed trading at $0.578, off by 0.34%, on 30,800 volume with 4 trades. The stock’s average daily volume over the past 60 days is 24,472, and its 52-week low/high is $0.51/$0.60.
Resort Savers, Inc. (RSSV) has built its reputation as an innovative environmental energy engineering company with expert diagnostic abilities and a diversified line of patented products. The company’s acquisition model seeks to identify innovative and market-ready petroleum industry technologies for installation and distribution throughout the Greater China market.
RSSV also has exclusive China rights for Worx America’s proprietary environmental engineering technologies as well as a 20% pre-IPO equity option. The Worx automated robotic systems quickly clean oil tanks and recover clean oil from waste sludge, resulting in increased sales and cost savings. The Worx multiple line of products and services give RSSV the capacity to offer proprietary solutions for onshore, offshore and subsea oil production, refining, cleaning and reclamation.
RSSV’s goal is to rapidly gain market share in China’s under-served oil tank cleaning and sludge processing industries through Worx technologies and on-ground training and installation. Senior management of Worx has been working in the field at RSSV’s China operations and has developed a training program for top engineers to go to Houston for further training and on-site systems installation and operations.
The company is led by a solid management team, owns a growing line of proprietary market-specific systems, and has positioned itself well as a high margin, competitive company. With a global focus, RSSV continues to pursue strategic partnerships and the licensing of key technologies for its extensive and growing customer base. Disclaimer
Resort Savers, Inc. Company Blog
Resort Savers, Inc. News:
Resort Savers, Inc. Closes $2M Investment
Resort Savers, Inc. Closes $700,000 Investment in Worx America
Resort Savers, Inc. Announces $2 Million Investment to Acquire Worx America, Inc. Interest
Dominovas Energy Corp. (DNRG)
The QualityStocks Daily Newsletter would like to spotlight Dominovas Energy Corp. (DNRG). Today, Dominovas Energy Corp. closed trading at $0.35, even for the day. The stock’s average daily volume over the past 60 days is 2,804 and its 52-week low/high is $0.06/$0.60.
Dominovas Energy Corp. (DNRG) is an energy solutions company dedicated to bringing clean, sensible and reliable power to areas of the world that lack this precious commodity. Recognizing the incredible growth and profit opportunities of the green and alternative energy markets, Dominovas Energy defined a sustainable deployment model to take a leading position among alternative green energy solutions providers.
At the heart of Dominovas Energy’s Fuel Cell Division is a revolutionary energy solution powered by the RUBICON™ Series Solid Oxide Fuel Cell (SOFC) Technology. Invented by inventor, scholar, professor and visionary Dr. Shamiul Islam, RUBICON™ achieves more than 50% fuel-to-electricity efficiency, providing cost effective, clean, significantly-reduced emissions with silent operations in 100kW to multi-megawatt power arrays. The proprietary system is capable of reforming and converting multiple fuel stocks, and is expected to become the “PLATINUM Standard” by which all other fuel cell technologies are measured.
In early 2014, Dominovas Energy was acquired by Western Standard Energy Corp. in a merger transaction in which Dominovas Energy was the emerging entity. Per the acquisition, Dominovas Energy obtained Western Standard’s 49.25% ownership of award-winning renewable energy company Pro Eco Energy Ltd. Pro Eco Energy provides award-winning heating and cooling systems for commercial and public buildings, delivering the newest alternative energy technologies for energy efficient HVAC systems in a timely and cost-competitive manner.
Dominovas Energy intends to build and own fuel cell utilities worldwide, joining the ranks of some of the world’s largest and most well-known companies that are already taking advantage of the vast opportunities of fuel cell systems. The RUBICON™ is far superior to any other system on the market today, and Dominovas Energy’s ability to produce a fuel cell that accepts multiple fuel sources is invaluable to meet the demands of the mass market. Disclaimer
Dominovas Energy Corp. Blog
Dominovas Energy Corp. News:
Dominovas Energy Corp. (DNRG) Key Management Featured in Exclusive QualityStocks Interview
Dominovas Energy Corp. Appoints International Business Professional to Board of Directors
Dominovas Energy and Delphi Sign MOU
eCareer Holdings, Inc. (ECHI)
The QualityStocks Daily Newsletter would like to spotlight eCareer Holdings, Inc. (ECHI). Today, eCareer Holdings, Inc. closed trading at $0.30, even for the day. The stock’s average daily volume over the past 60 days is 1,418 and its 52-week low/high is $0.20/$4.00.
eCareer Holdings, Inc. (ECHI) is an early-stage internet company working to organize the online hiring process by creating content-rich, profession-specific communities. By fully integrating its personalized career centers with matching branded professional and social networks, the company creates a solution for employers and professionals to enjoy the very best user experience.
The company’s development of branded career websites focuses on specialized “Internet Job Verticals,” which allow for some of the most effective job advertising platforms on the market. Through the use of superior technological solutions, eCareer Holdings plans to address the high demand for skilled professionals in a variety of narrow sectors while simultaneously attracting potential clients with strong advertising budgets.
Headquartered in Boca Raton, Florida, eCareer Holdings launched its first site, Openreq™, in January 2013. Using advanced software solutions, the site provides staffing, recruiting and human resource professionals with access to job openings in their desired sector. With a single post to Openreq, companies can reach over 1,300 sites including popular social networking destinations such as Indeed, Glassdoor, Facebook and SimplyHired. The company is also currently developing Cardiologist.com and BioFuel Zone, which are planned for release in the near future.
Led by a team of experienced executives headed by Chief Executive Officer Joseph J. Azzata, eCareer Holdings is persistently working to refine its effective job database solutions. With a range of unique features including industry news, social media groups, webinars, events, training programs and consolidated industry statistics, eCareer Holdings continues to engage in the design and development of revolutionary career websites aimed at recruiters, staffing companies and government agencies. Disclaimer
eCareer Holdings, Inc. Blog
eCareer Holdings, Inc. News:
eCareer Holdings Reports 1000% Increase in Openreq.com Site Traffic, Seeks to Expand Salesforce
eCareer Announces Engagement of QualityStocks Investor Relations Services
eCareer Relaunches Openreq With Revolutionary Job Matching Technology
Today's Top 3
Juicy Penny Stocks
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- Boreal Water Collection, Inc. (BRWC) Releases Open Letter to Shareholders
- Car Monkeys Group (CKMY) Announces Engagement of QualityStocks Investor Relations Services
- Cleartronic, Inc. (CLRI) Announces Expanded License Agreement With Collabria LLC
- Consorteum Holdings, Inc. (CSRH) Signs License Agreement With NYG Holdings
- Dominovas Energy Corp. (DNRG) Key Management Featured in Exclusive QualityStocks Interview
- eCareer Holdings, Inc. (ECHI) Reports 1000% Increase in Openreq.com Site Traffic, Seeks to Expand Salesforce
- Falcon Crest Energy (FCEN) Acquires Remaining Working Interest in Rocky Ford Field
- IFAN Financial, Inc. (IFAN) Reaches Technology Development Milestones
- International Stem Cell Corp. (ISCO) Announces Completion of Cell Bank for Parkinson's Disease Clinical Trial
- Inventergy Global, Inc. (INVT) Launches Standardized Licensing Initiative for Mobile Device Manufacturers
- MIT Holding, Inc. (MITD) Launches New Website with Investor Relations Suite
- Mobile Lads Corp. (MOBO) Purchases Majority of North American Shopping Network From Domark International
- One World Holdings, Inc. (OWOO) The One World Doll Project CEO Announces 2015 Revenue Projections in Stockholder Letter
- Pure Hospitality Solutions, Inc. (PNOW) anticipates $40 Million Oveedia Valuation with Divest and Focus Strategy
- Resort Savers, Inc. (RSSV) Closes $2M Investment
- Save The World Air, Inc. (ZERO) Sets Date for Its Year-End 2014 Earnings Results Release and Conference Call
- Sibling Group Holdings, Inc. (SIBE) Announces Strategic Partnership for Global Growth; $3.75 Million Investment to Grow Business in China and Other Markets
- Sparta Commercial Services, Inc. (SRCO) Reports Continued Sales Growth
- Start Scientific, Inc. (STSC) Signs Farmout Agreement With Durban Energy
- VistaGen Therapeutics, Inc. (VSTA) and NIH Sign Agreement for NIH-Sponsored Phase 2 Study of Orally-Active AV-101 in Major Depressive Disorder
- Well Power Inc. (WPWR) to host second webinar on proprietory micro-refinery technology
- Zenosense, Inc. (ZENO) Hospital Collaboration - 400 Person Lung Cancer Detection Trial